Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: MaxCyte Inc., 3 years.
MaxCyte Inc.
Director
Novavax Inc.
Director
Aldeyra Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 20, 2026 | Novavax Inc. | Option exercise | +18,880 | — | — |
| Jun 17, 2026 | MaxCyte Inc. | Grant or award | +30,421 | — | — |
| Mar 19, 2026 | Aldeyra Therapeutics Inc. | Open-market purchase | +70,000 | $1.40 | $98,000 |
| Aug 13, 2025 | MaxCyte Inc. | Open-market purchase | +80,000 | $1.39 | $111,200 |
| Jun 18, 2025 | MaxCyte Inc. | Grant or award | +29,210 | — | — |
| Jun 12, 2025 | Novavax Inc. | Option exercise | +10,420 | — | — |
| Jun 12, 2024 | Novavax Inc. | Option exercise | +6,670 | — | — |
| Jun 11, 2024 | MaxCyte Inc. | Grant or award | +21,367 | — | — |
| Jun 10, 2023 | Novavax Inc. | Option exercise | +3,100 | — | — |
| Mar 29, 2023 | MaxCyte Inc. | Open-market purchase | +80,000 | $4.32 | $345,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.